Cargando…

A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy

INTRODUCTION: BRCA1 inherited mutation carriers face a lifetime risk of 72% to develop breast cancer and a percentage of 44% risk for ovarian cancer. PRESENTATION OF CASE: We present a case of a 35-year old Caucasian woman who, after the excision of a possible malignant finding on the right breast,...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannos, Aris, Stavrou, Sofoklis, Douskos, Athanasios, Drakakis, Peter, Loutradis, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197605/
https://www.ncbi.nlm.nih.gov/pubmed/30340058
http://dx.doi.org/10.1016/j.ijscr.2018.10.014
_version_ 1783364802501935104
author Giannos, Aris
Stavrou, Sofoklis
Douskos, Athanasios
Drakakis, Peter
Loutradis, Dimitrios
author_facet Giannos, Aris
Stavrou, Sofoklis
Douskos, Athanasios
Drakakis, Peter
Loutradis, Dimitrios
author_sort Giannos, Aris
collection PubMed
description INTRODUCTION: BRCA1 inherited mutation carriers face a lifetime risk of 72% to develop breast cancer and a percentage of 44% risk for ovarian cancer. PRESENTATION OF CASE: We present a case of a 35-year old Caucasian woman who, after the excision of a possible malignant finding on the right breast, was diagnosed with ductal breast carcinoma. The patient treatment included first chemotherapy and radiotherapy and then prophylactic bilateral mastectomy with plastic reconstructive surgery. At the age of 37, she underwent prophylactic laparoscopic bilateral salpingoophorectomy. The histological diagnosis of the surgical specimens was suggestive of a unilateral invasive high grade salpingeal cancer and the patient underwent an abdominal hysterectomy by laparotomy, omentectomy and bilateral pelvic lymphadenectomy. DISCUSSION: Women with known BRCA mutations are strongly recommended to consider a risk reducing prophylactic salpingoophorectomy (RRSO) from their early 40 s to gain maximum benefit in cancer risk reduction from the procedure. The prevalence of occult carcinomas in BRCA1 carriers is almost 1, 5% if the prophylactic bilateral salpingoophorectomy is performed before the age of 40, while this percentage may be increased to 3, 8% for women who undergo the surgery between 40 and 49 years. CONCLUSION: We present an interesting case, of an accidentally revealed salpingeal carcinoma via RRSO in an asymptomatic young premenopausal woman.
format Online
Article
Text
id pubmed-6197605
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-61976052018-10-24 A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy Giannos, Aris Stavrou, Sofoklis Douskos, Athanasios Drakakis, Peter Loutradis, Dimitrios Int J Surg Case Rep Article INTRODUCTION: BRCA1 inherited mutation carriers face a lifetime risk of 72% to develop breast cancer and a percentage of 44% risk for ovarian cancer. PRESENTATION OF CASE: We present a case of a 35-year old Caucasian woman who, after the excision of a possible malignant finding on the right breast, was diagnosed with ductal breast carcinoma. The patient treatment included first chemotherapy and radiotherapy and then prophylactic bilateral mastectomy with plastic reconstructive surgery. At the age of 37, she underwent prophylactic laparoscopic bilateral salpingoophorectomy. The histological diagnosis of the surgical specimens was suggestive of a unilateral invasive high grade salpingeal cancer and the patient underwent an abdominal hysterectomy by laparotomy, omentectomy and bilateral pelvic lymphadenectomy. DISCUSSION: Women with known BRCA mutations are strongly recommended to consider a risk reducing prophylactic salpingoophorectomy (RRSO) from their early 40 s to gain maximum benefit in cancer risk reduction from the procedure. The prevalence of occult carcinomas in BRCA1 carriers is almost 1, 5% if the prophylactic bilateral salpingoophorectomy is performed before the age of 40, while this percentage may be increased to 3, 8% for women who undergo the surgery between 40 and 49 years. CONCLUSION: We present an interesting case, of an accidentally revealed salpingeal carcinoma via RRSO in an asymptomatic young premenopausal woman. Elsevier 2018-10-12 /pmc/articles/PMC6197605/ /pubmed/30340058 http://dx.doi.org/10.1016/j.ijscr.2018.10.014 Text en © 2018 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Giannos, Aris
Stavrou, Sofoklis
Douskos, Athanasios
Drakakis, Peter
Loutradis, Dimitrios
A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy
title A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy
title_full A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy
title_fullStr A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy
title_full_unstemmed A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy
title_short A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy
title_sort salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic brca1 carrier with breast malignancy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197605/
https://www.ncbi.nlm.nih.gov/pubmed/30340058
http://dx.doi.org/10.1016/j.ijscr.2018.10.014
work_keys_str_mv AT giannosaris asalpingealcarcinomarevealedafterprophylacticsalpingoophorectomyinanasymptomaticbrca1carrierwithbreastmalignancy
AT stavrousofoklis asalpingealcarcinomarevealedafterprophylacticsalpingoophorectomyinanasymptomaticbrca1carrierwithbreastmalignancy
AT douskosathanasios asalpingealcarcinomarevealedafterprophylacticsalpingoophorectomyinanasymptomaticbrca1carrierwithbreastmalignancy
AT drakakispeter asalpingealcarcinomarevealedafterprophylacticsalpingoophorectomyinanasymptomaticbrca1carrierwithbreastmalignancy
AT loutradisdimitrios asalpingealcarcinomarevealedafterprophylacticsalpingoophorectomyinanasymptomaticbrca1carrierwithbreastmalignancy
AT giannosaris salpingealcarcinomarevealedafterprophylacticsalpingoophorectomyinanasymptomaticbrca1carrierwithbreastmalignancy
AT stavrousofoklis salpingealcarcinomarevealedafterprophylacticsalpingoophorectomyinanasymptomaticbrca1carrierwithbreastmalignancy
AT douskosathanasios salpingealcarcinomarevealedafterprophylacticsalpingoophorectomyinanasymptomaticbrca1carrierwithbreastmalignancy
AT drakakispeter salpingealcarcinomarevealedafterprophylacticsalpingoophorectomyinanasymptomaticbrca1carrierwithbreastmalignancy
AT loutradisdimitrios salpingealcarcinomarevealedafterprophylacticsalpingoophorectomyinanasymptomaticbrca1carrierwithbreastmalignancy